

Lund, Sweden, Oct 4, 2017

## **Diaprost announces a Research and Option Agreement with a leading Pharmaceutical company**

**Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer.**

Diaprost announced today that it has signed an exclusive Licensing Agreement with a top 10 pharmaceutical company, under which its partner will develop a therapy against prostate cancer based on an antibody targeting human kallikrein-related peptidase 2 (hK2) discovered by Diaprost. Diaprost is a private pharmaceutical research and development company based in Lund, Sweden and whose principle asset is h11B6, the lead candidate in the hK2 antibody program. H11B6 is in pre-clinical development for prostate cancer, the most common cancer in men and has a high unmet medical need. The deal provides exclusive rights for the pharma partner to further develop Diaprost's therapeutic program with an option to acquire the asset at a later date.

“We believe the Licensing Agreement represents the best route to maximizing the potential of both Diaprost and the hK2 program,” said Johan Drott, the CEO of Diaprost. “Our partner has expertise in the prostate cancer therapy landscape, deep clinical development and regulatory experience and capabilities, and an established commercial infrastructure to deliver important new oncology therapies to patients.”

### **About Diaprost**

Diaprost was founded in 2005 based on the idea that the transformative success of the PSA assay for detection of prostate cancer could be leveraged as a personalized theranostic (therapy and diagnostic) platform. The technology and patent applications were pursued by researchers at Lund University in Sweden with support from private investors. Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Diaprost pipeline covers humanized antibodies for both diagnostic- and therapeutic applications targeting the hK2 antigen and therapy targeting the PSA antigen.

### **For more information, please contact:**

Johan Drott, CEO, Diaprost AB

+46 709 224 140

[johan.drott@diaprost.com](mailto:johan.drott@diaprost.com)